Unknown

Dataset Information

0

Variant Ciz1 is a circulating biomarker for early-stage lung cancer.


ABSTRACT: There is an unmet need for circulating biomarkers that can detect early-stage lung cancer. Here we show that a variant form of the nuclear matrix-associated DNA replication factor Ciz1 is present in 34/35 lung tumors but not in adjacent tissue, giving rise to stable protein quantifiable by Western blot in less than a microliter of plasma from lung cancer patients. In two independent sets, with 170 and 160 samples, respectively, variant Ciz1 correctly identified patients who had stage 1 lung cancer with clinically useful accuracy. For set 1, mean variant Ciz1 level in individuals without diagnosed tumors established a threshold that correctly classified 98% of small cell lung cancers (SCLC) and non-SCLC patients [receiver operator characteristic area under the curve (AUC) 0.958]. Within set 2, comparison of patients with stage 1 non-SCLC with asymptomatic age-matched smokers or individuals with benign lung nodules correctly classified 95% of patients (AUCs 0.913 and 0.905), with overall specificity of 76% and 71%, respectively. Moreover, using the mean of controls in set 1, we achieved 95% sensitivity among patients with stage 1 non-SCLC patients in set 2 with 74% specificity, demonstrating the robustness of the classification. RNAi-mediated selective depletion of variant Ciz1 is sufficient to restrain the growth of tumor cells that express it, identifying variant Ciz1 as a functionally relevant driver of cell proliferation in vitro and in vivo. The data show that variant Ciz1 is a strong candidate for a cancer-specific single marker capable of identifying early-stage lung cancer within at-risk groups without resort to invasive procedures.

SUBMITTER: Higgins G 

PROVIDER: S-EPMC3494940 | biostudies-literature | 2012 Nov

REPOSITORIES: biostudies-literature

altmetric image

Publications

Variant Ciz1 is a circulating biomarker for early-stage lung cancer.

Higgins Gillian G   Roper Katherine M KM   Watson Irene J IJ   Blackhall Fiona H FH   Rom William N WN   Pass Harvey I HI   Ainscough Justin F X JF   Coverley Dawn D  

Proceedings of the National Academy of Sciences of the United States of America 20121016 45


There is an unmet need for circulating biomarkers that can detect early-stage lung cancer. Here we show that a variant form of the nuclear matrix-associated DNA replication factor Ciz1 is present in 34/35 lung tumors but not in adjacent tissue, giving rise to stable protein quantifiable by Western blot in less than a microliter of plasma from lung cancer patients. In two independent sets, with 170 and 160 samples, respectively, variant Ciz1 correctly identified patients who had stage 1 lung canc  ...[more]

Similar Datasets

| S-EPMC5482839 | biostudies-other
| S-EPMC5978993 | biostudies-literature
| S-EPMC3259258 | biostudies-literature
| S-EPMC5295844 | biostudies-literature
| S-EPMC6407000 | biostudies-literature
| S-EPMC6775270 | biostudies-literature
| S-EPMC4939988 | biostudies-literature
| S-EPMC8202280 | biostudies-literature